2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Period 2nd Quarter 2011 Filed Jul 19, 2011 Signed by Samantha Ventimiglia, Senior Director, Government Affairs and Public Policy

Official filing
Firm
VERTEX PHARMACEUTICALS INCORPORATED
Client
VERTEX PHARMACEUTICALS INCORPORATED
Income
—
Expenses
$450,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2012 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S 23/HR 1249 America Invents Act, provisions related to supplemental examination, fee diversion, and first inventor to file.

LobbyistCovered position, as disclosed
RACHEL WHITEFORD MACK —
RICHARD WAYNE OLSON New Legal Fellow, House Cmte Energy & Commerce
AMIT K SACHDEV —
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); SENATE

Bills named: H.R. 1249 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.